

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

CD3 Monoclonal Antibody (17A2), Alexa Fluor™ 532, eBioscience

RRID:AB_11217479

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 58-0032-82, RRID:AB_11217479)

Antibody Information

URL: http://antibodyregistry.org/AB_11217479

Proper Citation: (Thermo Fisher Scientific Cat# 58-0032-82, RRID:AB_11217479)

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow

Antibody Name: CD3 Monoclonal Antibody (17A2), Alexa Fluor™ 532, eBioscience

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Defining Citation: [PMID:11884483](#)

Antibody ID: AB_11217479

Vendor: Thermo Fisher Scientific

Catalog Number: 58-0032-82

Alternative Catalog Numbers: 58-0032

Record Creation Time: 20251213T073938+0000

Record Last Update: 20260225T231149+0000

Ratings and Alerts

No rating or validation information has been found for CD3 Monoclonal Antibody (17A2), Alexa Fluor™ 532, eBioscience.

No alerts have been found for CD3 Monoclonal Antibody (17A2), Alexa Fluor™ 532, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Alzeeb G, et al. (2024) Efficacy of novel allogeneic cancer cells vaccine to treat colorectal cancer. *Frontiers in oncology*, 14, 1427428.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. *Cancer cell*, 41(5), 837.

Denis M, et al. (2022) Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy. *Frontiers in immunology*, 13, 1011943.

Fox A, et al. (2020) Acquisition of High-Quality Spectral Flow Cytometry Data. *Current protocols in cytometry*, 93(1), e74.

Baptista AP, et al. (2019) The Chemoattractant Receptor Ebi2 Drives Intranodal Naive CD4+ T Cell Peripheralization to Promote Effective Adaptive Immunity. *Immunity*, 50(5), 1188.